MEDIPOST (subsidiary company_EVASTEM)

What MEDIPOST (subsidiary company_EVASTEM) does

MEDIPOST is a South Korea-based, KOSDAQ-listed biotechnology company (ticker 203940, founded 2000) that develops and commercializes allogeneic umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) therapeutics, anchored by CARTISTEM — the world's first approved allogeneic cord blood MSC therapy for knee osteoarthritis (MFDS approval January 2012), now completed Japan Phase 3 and in active US Phase 3. The company is organized around a vertically integrated stem cell platform combining the proprietary SMUP-Cell small-sized, ultra-potent cell selection technology, validated large-scale GMP manufacturing (CellSTACK 10-layer through HYPERStack 36-layer vessels, 99%+ production success rate, ≤6-hour fill/finish), and a second-generation pipeline (SMUP-IA-01, SMUP-IV-01-DNP, SMUP-IV-01-ARDS) targeting osteoarthritis, diabetic nephropathy, and ARDS. Its competitive moat rests on regulatory first-mover status, 36,000+ cumulative real-world treatments with 13+ years of published clinical data, and 95+ patents across 16+ countries.

Beyond therapeutics, MEDIPOST operates four revenue-generating business lines through wholly owned subsidiaries: Celltree (Korea's leading cord blood bank with 337,956 units stored and 567 transplant cases), MOVITA (health functional foods distributed through 153 Korean hospitals and major e-commerce platforms), Lucatree (premium adult-derived regenerative medicine banking launched 2025), and CDMO services for cell and gene therapy developers. Commercialization is hybrid: direct hospital/KOL sales in Korea for CARTISTEM, an exclusive Japan distribution license with Teikoku Seiyaku (170-year Japanese pharma) including ~266B KRW in upfront and milestone payments, a strategic North American manufacturing partnership with OmniaBio (Health Canada DEL approved September 2025), and dedicated US (MEDIPOST Inc., Cambridge MA) and Japan (MEDIPOST K.K., Tokyo) subsidiaries. In 2025 the company raised approximately 2,050B KRW from existing and external investors to fund global clinical development.

Name

MEDIPOST (subsidiary company_EVASTEM)

Legal name

메디포스트(주)

Website

https://medi-post.co.kr

Company type

Public

Founded year

2000

Operating status

Operating

Short description

MEDIPOST is a KOSDAQ-listed Korean biotech that develops allogeneic cord blood-derived mesenchymal stem cell therapies — led by CARTISTEM (knee osteoarthritis, approved in Korea since 2012, US Phase 3 ongoing) — and operates cord blood banking (Celltree), health functional foods (MOVITA), adult regenerative banking (Lucatree), and cell therapy CDMO services.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy CDMO (HLAGABAD)

Keywords

• Stem cell therapeutics
• Regenerative medicine
• Cord blood banking
• Cell therapy CDMO
• Biologic drug manufacturing

Headquarters

HQ city

Seongnam-si (Bundang-gu)

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Stem Cell Therapeutics (CARTISTEM): Revenue from sales of CARTISTEM in Korea, currently the only commercialized product. Sales are through hospital/clinic channels with pricing influenced by national health insurance reimbursement. Approximately 3.6万+ cumulative treatments administered since 2012 approval.
2. CDMO Services: Contract development and manufacturing services for cell therapy developers. Services include process development, tech transfer, GMP manufacturing, quality control, and regulatory filing support. End-to-end services from research to commercialization.
3. Celltree Cord Blood Banking: Cord blood collection, processing, and long-term cryopreservation services. Revenue from both initial banking fees and annual storage/maintenance fees.
4. MOVITA Health Functional Foods: Health functional food brand sold through hospitals, online channels (self-operated mall, Naver, Coupang, Kurly), and retail pharmacy partnerships. Products include supplements for pregnant women, infants, children, adults, and seniors.
5. Lucatree Advanced Regenerative Medicine: Premium regenerative medicine brand offering stem cell and immune cell banking services derived from adult adipose tissue and blood. Future-oriented health asset preservation for anticipated regenerative medicine applications.
6. Japan Licensing & Milestones (Teikoku Seiyaku): Upfront payment of approximately 118 billion KRW received for Japan exclusive sales rights of CARTISTEM. Additional milestone payments of approximately 148 billion KRW upon regulatory approval. Long-term sales milestones and API/finished product supply revenue to follow commercial launch in Japan.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

MEDIPOST develops, manufactures, and commercializes allogeneic umbilical cord blood-derived mesenchymal stem cell therapies (CARTISTEM for knee osteoarthritis and PNEUMOSTEM for COPD) built on its proprietary SMUP platform. The company also operates a cord blood banking service (Celltree), health functional food products (Movita), advanced regenerative medicine offerings through subsidiary EVASTEM (Lucatree), and contract development/manufacturing (CDMO) services for cell therapies.

Product overview

MEDIPOST is a global leader in stem cell therapeutics with a portfolio of 1st and 2nd generation cord blood-derived mesenchymal stem cell therapies. The 1st generation includes CARTISTEM® (approved in Korea for knee cartilage defects, completing Japan Phase 3, entering US Phase 3) and PNEUMOSTEM® (for bronchopulmonary dysplasia in Phase 2). The 2nd generation SMUP-Cell platform includes SMUP-IA-01 (injectable osteoarthritis treatment completing Phase 2), SMUP-IV-01-DNP (diabetic nephropathy in preclinical), and SMUP-IV-01-ARDS (ARDS in preclinical). Supporting businesses include Celltree cord blood bank (337,956 units stored, market leader), Movita health functional foods (distributed in 153 hospitals), Lucatree regenerative medicine services, and CDMO contract manufacturing services. The company operates GMP-certified facilities in Seoul and maintains global partnerships with OmniaBio in Canada for North American clinical supply.

Differentiator

Problem solved

Functional benefit

Brands

• CARTISTEM: Allogeneic cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis (ICRS grade IV cartilage defect treatment)
• PNEUMOSTEM
• SMUP-Cell
• Celltree
• Movita
• Lucatree
• Immunique

Quantifiable outcome

• CARTISTEM showed 98% ICRS grade improvement vs 71% for microfracture in Korean Phase 3 (2012 approval)
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, minor and major.

• Teikoku Seiyaku (테이코쿠 제약)coreChannel Partner/ Reseller/ Distributor · 1 December 2025Teikko Seiyaku (170-year-old Japanese pharmaceutical company) holds exclusive sales rights for CARTISTEM in Japan. MEDIPOST receives upfront payment of ~118 billion KRW, regulatory milestone of ~148 billion KRW, and additional long-term sales milestones. MEDIPOST supplies finished product from Korea. The partnership was signed in December 2025, with BLA filing planned for 2H26 and approval expected in 2027.
• OmniaBio Inc. (옴니아바이오)coreChannel Partner/ Reseller/ Distributor · 1 January 2022OmniaBio is MEDIPOST's strategic CDMO partner for North American clinical trials and commercialization. Located in Hamilton, Ontario, Canada with a 100,000 sq.ft. GMP facility (opened October 2024). OmniaBio received Health Canada Drug Establishment License approval in September 2025. OmniaBio provides cell and gene therapy manufacturing services for MEDIPOST's CARTISTEM US clinical trials.
• Immunique Co., Ltd. (이뮤니크)minorStrategic or Co-development Partner · 1 January 2021MEDIPOST established Immunique as a specialized subsidiary focused on cord blood-derived immune cell therapy. The subsidiary develops new cell therapy products using the parent company's umbilical cord blood technology platform.
• ExcelSera Therapeutics (엑셀세라퓨틱스)majorTechnology or Integration · 1 January 2020Partnership to develop and apply domestically manufactured chemically defined cell culture media (CellCor™ MSC CD AOF) for CARTISTEM production. This replaces animal-derived components, enhancing safety and homogeneity. Selected for the Ministry of Trade, Industry and Energy's 'SME Champion Enterprise' program with 13 billion KRW total project budget. Project runs from September 2023 to December 2026. PMDA DMF registration and equivalence testing targeted for early next year.
• Shandong Yuansheng Pharmaceutical Co., Ltd. (산동원생제약유한공사)minorChannel Partner/ Reseller/ Distributor · 1 January 2015Joint venture company established in China for potential future business development in the Chinese market. Part of MEDIPOST's regional expansion strategy in Asia.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Emerging players

• Athersys: US clinical-stage cell therapy company developing MultiStem (multipotent adult progenitor cells) for stroke, ARDS, and trauma. Comparable emerging allogeneic cell therapy developer with similar Phase 3-stage clinical programs.
• Cynata Therapeutics: Australian clinical-stage biotech developing CYP-001, an iPSC-derived MSC therapy for graft-versus-host disease and osteoarthritis. Comparable emerging MSC platform targeting musculoskeletal indications with novel manufacturing approach.
• BrainStorm Cell Therapeutics: Clinical-stage cell therapy company developing NurOwn (autologous MSC-based therapy) for ALS and multiple sclerosis. Comparable emerging cell therapy developer with late-stage clinical assets in neurodegenerative indications.
• Hope Biosciences: US clinical-stage biotech developing autologous and allogeneic adipose-derived MSC therapies for various indications. Comparable emerging player in MSC therapeutics with focus on cell banking and therapeutic product development.

Direct peers

• Mesoblast: Australian biotech developing remestemcel-L, an allogeneic MSC therapy for inflammatory conditions including osteoarthritis and acute graft-versus-host disease. Most direct peer given shared MSC platform targeting musculoskeletal indications.
• Cryo-Cell International: US-based cord blood banking company offering private and public cord blood storage services. Comparable direct peer in the cord blood banking business segment of MEDIPOST's Celltree operations.
• Corestem: Korean biotech developing autologous bone marrow-derived MSC therapy (Neuromold) for ALS. Closest Korean domestic peer with overlapping MSC therapy development and similar regulatory pathway through MFDS.
• Pluristem Therapeutics: Israeli biotech developing placenta-derived MSC-like adherent stromal cell therapies (PLX cells) for multiple indications including musculoskeletal and inflammatory conditions. Comparable allogeneic off-the-shelf cell therapy business model.

Broad incumbents

• JCR Pharmaceuticals: Japanese pharmaceutical company that markets TEMCELL HS, an allogeneic MSC therapy approved in Japan for acute graft-versus-host disease. Most relevant Japanese incumbent competitor with an approved MSC product and existing Japanese commercial infrastructure.
• Takeda Pharmaceutical (TiGenix): Global pharmaceutical major that acquired TiGenix and now commercializes darvadstrocel (Cx601), an allogeneic adipose-derived MSC therapy for Crohn's perianal fistulas. Represents an established large-pharma competitor in approved allogeneic cell therapy commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medi-post

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDIPOST (subsidiary company_EVASTEM)